Karuna Therapeutics, Inc.
KRTXDelisted Mar 18, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001771917
Karuna Therapeutics, Inc. was delisted on Mar 18, 2024; its insiders filed their last Form 4 on Mar 18, 2024; 328 institutions reported holding it in 13F filings for Q4 2023, worth $12.0B in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Karuna Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Karuna Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Jonas Jeffrey M | Director | 0 | Mar 18, 2024 | 0 |
| Coughlin Christopher J | Director | 0 | Mar 18, 2024 | 0 |
| Paul Steven M | Director | 0Indirect | Mar 18, 2024 | 0 |
| Healy James | Director | 0Indirect | Mar 18, 2024 | 0 |
| Meury William | President and CEO | 0 | Mar 18, 2024 | 0 |
| Olson Laurie J | Director | 0 | Mar 18, 2024 | 0 |
| Pande Atul | Director | 0 | Mar 18, 2024 | 0 |
| Brannan Stephen K. | Chief Medical Officer | 0 | Mar 18, 2024 | 0 |
| Miller Andrew Craig | President of R&D | 0 | Mar 18, 2024 | 0 |
| Wheadon David E. | Director | 0 | Mar 18, 2024 | 0 |
| Kane William P Jr | Chief Commercial Officer | 0 | Mar 18, 2024 | 0 |
| Torres Denice | Director | 0 | Mar 18, 2024 | 0 |
| Brown Jason Parker | Chief Financial Officer | 0 | Mar 18, 2024 | 0 |
| Ignelzi Troy A. | Chief Financial Officer | 30,487 | Aug 24, 2023 | 0 |
| Lykins Charmaine | Chief Commercial Officer | – | Nov 30, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 3, 2022 (view filing) | Jan 3 | Same day | Brannan Stephen K.Chief Medical Officer | SSale | −7.73K | $130.79 | −$1.01M | −25.6%22.5K after | |
| Jan 3, 2022 (view filing) | Jan 3 | Same day | Pande AtulDirector | SSale | −2.50K | $130.44 | −$326.1K | −100.0%0 after | |
| Dec 2, 2021 (view filing) | Dec 1 | 1 day | Pande AtulDirector | SSale | −2.50K | $127.73 | −$319.3K | −100.0%0 after | |
| Dec 2, 2021 (view filing) | Dec 1 | 1 day | Brannan Stephen K.Chief Medical Officer | SSale | −7.73K | $127.57 | −$985.9K | −27.9%20.0K after | |
| Nov 15, 2021 (view filing) | Nov 15 | Same day | Olson Laurie JDirector | SSale | −1.00K | $138.24 | −$138.2K | −100.0%0 after | |
| Nov 10, 2021 (view filing) | Nov 8 | 2 days | Ignelzi Troy A.Chief Financial Officer | SSale | −13.5K | $152.32 | −$2.06M | −42.9%18.0K after | |
| Nov 3, 2021 (view filing) | Nov 1 | 2 days | Miller Andrew CraigChief Operating Officer | SSale | −2.83K | $142.03 | −$401.5K | −5.2%51.5K after | 6 lots |
| Nov 3, 2021 (view filing) | Nov 1 | 2 days | Brannan Stephen K.Chief Medical Officer | SSale | −7.73K | $136.67 | −$1.06M | −30.6%17.5K after | 2 lots |
| Nov 3, 2021 (view filing) | Nov 1 | 2 days | Pande AtulDirector | SSale | −2.50K | $136.67 | −$341.7K | −100.0%0 after | |
| Oct 5, 2021 (view filing) | Oct 1-4 | 4 days | Miller Andrew CraigChief Operating Officer | SSale | −16.5K | $124.36 | −$2.05M | −37.2%27.8K after | 7 lots |
| Oct 1, 2021 (view filing) | Oct 1 | Same day | Pande AtulDirector | SSale | −2.50K | $120.72 | −$301.8K | −100.0%0 after | |
| Sep 10, 2021 (view filing) | Sep 8-10 | 2 days | Ignelzi Troy A.Chief Financial Officer | SSale | −10.0K | $117.38 | −$1.17M | −35.7%18.0K after | 4 lots |
| Sep 3, 2021 (view filing) | Sep 1-2 | 2 days | Miller Andrew CraigChief Operating Officer | SSale | −8.17K | $120.78 | −$987.2K | −15.6%44.3K after | 4 lots |
| Sep 1, 2021 (view filing) | Sep 1 | Same day | Pande AtulDirector | SSale | −2.50K | $117.82 | −$294.6K | −100.0%0 after | |
| Aug 18, 2021 (view filing) | Aug 16 | 2 days | Miller Andrew CraigChief Operating Officer | SSale | −5.50K | $103.92 | −$571.6K | −9.5%52.5K after | 3 lots |
| Aug 18, 2021 (view filing) | Aug 17-18 | 1 day | Paul Steven MPRESIDENT & CEO | PPurchase | +2.36K | $105.86 | +$250.3K | +2.2%108.8K after | 2 lots |
| Aug 2, 2021 (view filing) | Aug 2 | Same day | Pande AtulDirector | SSale | −2.50K | $114.17 | −$285.4K | −100.0%0 after | |
| Jul 7, 2021 (view filing) | Jul 2 | 5 days | Healy JamesDirector | PPurchase | +636 | $117.80 | +$74.9K | New position636 after | |
| Jul 1, 2021 (view filing) | Jul 1 | Same day | Pande AtulDirector | SSale | −2.50K | $112.66 | −$281.6K | −100.0%0 after |